U.S. Pharmaceuticals & Biotech Buy the Dip

4D Molecular Therapeutics

Market Cap: US$526.4m

A late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.

Zentalis Pharmaceuticals

Market Cap: US$308.2m

A clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States.

MacroGenics

Market Cap: US$235.2m

A clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.

Adagene

Market Cap: US$211.4m

A clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People’s Republic of China.

Kazia Therapeutics

Market Cap: US$140.1m

Operates as an oncology-focused biotechnology company in Israel.

PepGen

Market Cap: US$133.5m

A clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.

Cumberland Pharmaceuticals

Market Cap: US$99.0m

A specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products.

Numinus Wellness

Market Cap: US$12.8m

Provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States.